Can Afinitor (everolimus) be reimbursed?

Will patients with advanced renal cancer be able to get cheaper and better drugs this year? Now all eyes are on the National Health Insurance Corporation’s decision on the price of Novartis Afinitor (everolimus), the second-line treatment for the disease.

Afinitor is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafe...